期刊文献+

吡拉西坦与奥拉西坦对老年脑出血后认知功能障碍的疗效比较 被引量:35

Comparison on effects of piracetam and oxiracetam on elderly cognitive dysfunction after cerebral hemorrhage
原文传递
导出
摘要 目的对比分析吡拉西坦与奥拉西坦对老年脑出血后认知功能障碍的治疗效果。方法选择2012年1月~2015年12月在铜川市人民医院进行诊治的老年脑出血患者82例,按照治疗药物的不同分为吡拉西坦组和奥拉西坦组,分别采用吡拉西坦和奥拉西坦进行治疗。比较两组治疗前后的蒙特利尔认知评估量表(Mo CA)、简易精神状态检查量表(MMSE)和日常生活能力量表(ADL)评分,以及治疗1、3、6个月后的神经元特异烯醇化酶水平和认知功能改善情况。结果治疗后,两组的Mo CA、MMSE、ADL评分均明显改善(P<0.05),且奥拉西坦组明显优于吡拉西坦组(P<0.05);与治疗1个月相比,两组治疗6个月的Mo CA、MMSE、ADL显效率及总有效率均明显升高(P<0.05),且奥拉西坦组明显优于吡拉西坦组(P<0.05);两组治疗1、3、6个月后的神经元特异烯醇化酶水平均较治疗前明显降低(P<0.05),且奥拉西坦组在治疗3、6个月的神经元特异烯醇化酶水平明显低于吡拉西坦组(P<0.05);两组的不良反应发生率相比无明显差异。结论奥拉西坦改善老年脑出血后认知功能障碍的效果较吡拉西坦更佳,且疗效随着用药时间的延长而增加,并能降低神经元特异烯醇化酶水平,具有较高的临床应用价值。 Objective To compare the effects of piracetam and oxiracetam on elderly cognitive dysfunction after cerebral hemorrhage. Methods Elderly patients(82 cases) with cerebral hemorrhage treated in Tongchuan People's Hospital from January 2012 to December 2015 were selected and divided into two groups according to the different treatment drugs. Two groups were treated by oxiracetam and piracetam respectively. The Montreal cognitive assessment scale(Mo CA), simple mental state examination(MMSE), and daily life ability scale(ADL) score of the two groups before and after treatment were compared. The neuron-specific enolase levels and cognitive function after treatment of 1, 3, and 6 months were also compared. Results After treatment, Mo CA, MMSE, and ADL scores of two groups were significantly improved(P〈0.05), and oxiracetam group were significantly better than piracetam group(P〈0.05). After treatment 6 months, Mo CA, MMSE, ADL effective and total effective rate of the two groups were significantly higher(P〈0.05), and oxiracetam group were significantly better than those of piracetam group(P〈0.05). After treatment for 1, 3, and 6 months, the neuron-specific enolase levels were significantly lower than those before treatment(P〈0.05), and in the treatment of 3 and 6 months, oxiracetam group were significantly lower than piracetam group(P〈0.05). The incidence of adverse reactions had no significant difference. Conclusion Oxiracetam can improve the elderly cognitive dysfunction after cerebral hemorrhage, the curative effect was increased with the prolonging of the time, and can reduce the neuron-specific enolase levels, which has high clinical value.
出处 《药物评价研究》 CAS 2017年第2期229-232,共4页 Drug Evaluation Research
关键词 吡拉西坦 奥拉西坦 认知功能障碍 脑出血 蒙特利尔认知评估量表 简易精神状态检查量表 日常生活能力量表 神经元特异烯醇化酶 piracetam oxiracetam cognitive dysfunction cerebral hemorrhage MoCA MMSE ADL neuron-specific enolase
  • 相关文献

参考文献3

二级参考文献35

  • 1Hachinski V, ladecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke, 2006,37:2220-2241.
  • 2Chui HC, Nielsen-Brown N. Vascular cognitive impairment. Continuum Lifelong Learning Neurol, 2007,13 : 109-143.
  • 3Chui HC. Vascular cognitive impairment: Today and tomorrow. Alzheimer's and Dementia,2006,2 : 185-194.
  • 4Bowler JV, Gorelick PB. Advances in vascular cognitive impairment 2006. Stroke,2007,38:241-244.
  • 5O'Brien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry, 2006,14:724-733.
  • 6Seines OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol, 2006,2:538-547.
  • 7Erkinjuntti T. Subcortical vascular dementia. Cerebrovasc Dis, 2002,13 Suppl 2:58-60.
  • 8Mackowiak-Cordoliani MA, Bombois S, Memin A, et al. Poststroke dementia in the elderly. Drugs Aging, 2005,22:483- 493.
  • 9Pohjasvaara T, Mantyla R, Ylikoski R, et al. Clinical features of MRI-defined subcortical vascular disease. Alzheimer Dis Assoc Disord ,2003,17:236-242.
  • 10Reed BR, Mungas DM, Kramer JH, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain,2007,130( Pt 3 ) :731- 739.

共引文献280

同被引文献261

引证文献35

二级引证文献151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部